3 ASX Growth Stocks Backed By Strong Balance Sheets

Eurozone consumer confidence has reached a new high for 2026, and services activity remains solid. That points to households that feel more secure and are still spending, which can support companies with healthy balance sheets and clear earnings growth potential. The Healthy High Growth Potential screener filters for exactly those kinds of stocks. This article highlights three of the strongest candidates worth having on your radar now.

The stocks covered below are just a sample of this theme. The full screen surfaces 93 more companies that share similar growth profiles and financial resilience but are not featured in this article. To go beyond the highlights and identify your own highest conviction ideas, head straight into the Healthy high growth potential screener.

Overview: Mesoblast is a biotech company developing regenerative cell therapies, built around mesenchymal lineage cells, that target severe inflammatory and cardiovascular conditions such as steroid refractory acute graft versus host disease, inflammatory bowel diseases, chronic heart failure and chronic low back pain. Its lead therapy Remestemcel L and related MPC products are in Phase III trials across several of these indications. This anchors its fit with the healthy high growth potential theme, while the broader pipeline and partnerships add some diversification.

Operations: Mesoblast currently generates around US$65 million in revenue from the development and commercialization of its cell technology platform.

Market Cap: A$3.1 billion

Mesoblast gives you exposure to late stage regenerative medicine programs, with Remestemcel L and MPC therapies in Phase III trials for conditions where treatment gaps remain significant. The company already has the first FDA approved mesenchymal stromal cell product in the US and more than 1,100 patents, alongside expanding use of Ryoncil in pediatric steroid refractory acute GvHD and potential label extensions into larger adult and chronic indications. The flip side is clear: Mesoblast is still loss making, heavily reliant on successful trial outcomes and external funding, and carries valuation risk if milestones slip. For investors focused on high growth potential, that mix of pipeline depth and execution risk is what makes Mesoblast a company that may warrant a closer look.

Mesoblast’s late stage cell therapy story looks powerful, yet the real hinge is how current expectations stack up against what analysts see ahead. Before you decide how it fits your portfolio, scan the analyst forecasts for Mesoblast and spot the assumption that could flip this thesis on its head.

Overview: Westgold Resources is a Perth based gold producer focused on exploring, developing, and operating gold mines across its Murchison and Southern Goldfields hubs in Western Australia. The company’s inclusion in the Healthy high growth potential theme is mainly tied to its expanding production pipeline at these operations. Higher throughput and resource conversion are expected to be the key earnings drivers over the next few years.

Operations: Westgold Resources generates essentially all of its A$2.0 billion revenue from its Murchison operations at about A$1.3 billion and Southern Goldfields at about A$691 million, all within Australia.

Market Cap: A$6.0 billion

Westgold Resources is worth a closer look if you want pure gold exposure backed by concrete growth projects rather than just hopes about the gold price. The company is scaling output at Murchison and Southern Goldfields, with new reserves at the Fletcher zone, planned Higginsville and Cue plant expansions, and a capital light throughput lift that targets extra production from FY28. At the same time it holds a large cash and liquidity pool and has been selling non core assets, which supports the balance sheet while growth capex ramps. The risk is clear though, since the story relies on converting growing resource estimates into higher grade ore and managing rising costs, and any slip in integration or execution could affect the earnings path that the Healthy high growth potential screen is flagging.

Westgold Resources appears to be demonstrating production growth in motion, supported by a sizeable cash and liquidity pool that many investors may be underestimating. Before you move on, read the full Westgold Resources financial health report

Overview: Lynas Rare Earths is a vertically integrated rare earths producer that mines ore at Mt Weld in Western Australia and processes it through plants in Kalgoorlie and Gebeng to supply praseodymium and neodymium rich concentrates and separated oxides used in permanent magnets for electric vehicles and wind turbines, which is the direct link to the Healthy high growth potential theme. The company also produces a broader mix of light and heavy rare earth oxides and runs advanced materials and corporate services that support its core rare earths business.

Operations: Lynas Rare Earths generates about A$715.9 million in revenue from its Rare Earth Operations segment.

Market Cap: A$16.5 billion

Lynas Rare Earths provides focused exposure to rare earth materials that feed directly into EV and wind turbine magnets. The company operates its Mt Weld, Kalgoorlie and Gebeng assets as an integrated chain and combines this structure with an experienced board. However, funding is sourced from higher risk capital and the business is concentrated in a relatively narrow product set, so any policy or pricing shock could affect earnings. For investors seeking exposure to the rare earth supply chain within a Healthy high growth potential framework, this is a business that may warrant closer research and consideration.

Lynas Rare Earths links EV and wind growth to a tightly controlled supply chain, yet many readers may not have seen how consensus expectations line up with that story. Scan the analyst forecasts for Lynas Rare Earths and see what assumption might be hiding in plain sight.

Seeking Fresh Alternatives Before They Fly

Markets move fast and the strongest ideas rarely stay under the radar for long. Spot fresh momentum, catch potential breakouts before the crowd, and act now.

• Spot early movers in digital assets by tracking companies tied to blockchain, exchanges, and payment rails through the curated 20 cryptocurrency and blockchain stocks before sentiment shifts and opportunities get crowded.
• Target potential cash generators with pricing power by scanning the curated 5 dividend fortresses while yields remain elevated and volatility keeps income opportunities mispriced.
• Hunt for potential core portfolio anchors by reviewing the hand picked list of solid balance sheet and fundamentals (21 results) before tightening conditions reward stronger balance sheets and leave weaker stocks dropping.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com